Keralam SMA Drug Controversy Sparks Debate Over Procurement and Transparency
The controversy in Keralam involves the distribution of a generic drug for spinal muscular atrophy (SMA) at SAT Hospital, with opposition leaders, including CPI(M) and Pinarayi Vijayan, questioning the government's procurement procedures and transparency. Health Minister K. Muraleedharan defended the drug's safety and decision-making by expert committees, attributing concerns to media reports and alleged pharmaceutical company interests. The opposition supports generic medicines but criticizes the government's handling and communication with affected families, calling for a thorough investigation.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. Coverage leans balanced overall (Left 10%, Centre 60%, Right 30%). Overall sentiment is negative (39/100). Lens Score 66/100.
Outlets measured: thehindu, news18, theprint, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 4 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (32–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 23 Oct, 03:52 pm. Other outlets followed.